Selonsertib is an investigational drug categorized as a selective apoptosis signal-regulating kinase 1 (ASK1) inhibitor, primarily studied for its potential in treating diseases such as non-alcoholic steatohepatitis… Read more
Selonsertib is an investigational drug categorized as a selective apoptosis signal-regulating kinase 1 (ASK1) inhibitor, primarily studied for its potential in treating diseases such as non-alcoholic steatohepatitis (NASH), diabetic nephropathy, and various kidney and liver disorders. By targeting the ASK1 pathway, this compound aims to mitigate inflammation and fibrosis associated with these conditions. Laboratories and pharmaceutical researchers utilize high-quality Selonsertib reference standards, including identified impurities, degradants, and metabolites, to conduct essential impurity profiling and method validation. Furthermore, the inclusion of stable isotope-labelled compounds is critical for accurate quantification and analytical testing via mass spectrometry, ensuring robust quality control during clinical development and manufacturing processes. These materials support the rigorous characterization required to assess the safety and efficacy of the drug substance throughout its lifecycle.